Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg levonorgestrel (approximately 20 µg/day release) intrauterine system for intrauterine use. It provides birth control and reduces heavy menstrual bleeding in women of reproductive age, and is approved in the European Union.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing a reliable, quality‑assured source for this EU‑approved intrauterine system.

Mirena, a levonorgestrel intrauterine system, acts within the reproductive hormonal pathway to provide contraceptive and menstrual management benefits.

- Long‑term contraception: provides up to five years of highly effective birth control. - Management of heavy menstrual bleeding: reduces menstrual blood loss and improves quality of life. - Endometrial protection in hormone therapy: helps prevent endometrial hyperplasia when combined with estrogen therapy.

Adverse reactions to Mirena may vary in frequency and severity.

Common Side Effects: - Irregular bleeding or spotting: unpredictable bleeding patterns, especially in the first months. - Amenorrhea: absence of menstrual periods after prolonged use. - Headache: mild to moderate headache episodes. - Breast tenderness: discomfort or swelling of the breasts.

Serious or Rare Side Effects: - Uterine perforation: rare injury to the uterine wall during insertion. - Pelvic inflammatory disease: infection that can spread to reproductive organs. - Ectopic pregnancy: pregnancy occurring outside the uterus if contraception fails. - Hormone‑dependent tumor growth: potential stimulation of existing breast or ovarian tumors.

Precautions should be observed to ensure safe use of Mirena.

- Patient selection: confirm no active pelvic infection or uterine anomalies before insertion. - Pregnancy status: contraindicated in known or suspected pregnancy (Category X). - Breastfeeding: assess risk‑benefit; may be used but discuss with a clinician. - Smoking: advise cessation, especially in women over 35, due to increased cardiovascular risk. - Follow‑up: schedule pelvic exam 4–6 weeks after insertion to verify placement. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Drug interactions may affect the efficacy or safety of Mirena.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampin and other strong CYP3A4 inducers: can lower hormone levels, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel exposure, monitor for side effects. - Antiretroviral protease inhibitors (e.g., ritonavir): may alter hormone metabolism, assess efficacy. - Herbal supplements containing St. John’s wort: possible reduction in effectiveness, advise caution.